Revolution Medicines, Inc.
RVMD
#553
Rank
$46.177 B
Marketcap
United States
Country
$215.44
Share price
4.81%
Change (1 day)
341.06%
Change (1 year)
Categories
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to…
Key Metrics
Trailing P/E
—
Forward P/E
-34.23
EPS (TTM)
$-8.86
Forward EPS
$-5.95
Price / Book
16.75
EV / EBITDA
-25.3x
Beta
1.41
Dividend Yield
—
Return on Equity
-79.09%
Return on Assets
-30.12%
Debt / Equity
45.68
Current Ratio
11.38
Gross Margin
0.00%
Operating Margin
0.00%
Net Profit Margin
0.00%
Free Cash Flow
$-711,607,360
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 13 – Sep 11
+0.88%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$11.580M
Latest Net Income$-436,367,000
Reporting periods2
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Revolution Medicines, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
RVMD
No recent news available. Set FINNHUB_API_KEY to enable news.
